glp1.app valid

Automatically discovered from public files. Ownership management is optional. Inclusion does not imply endorsement or publisher participation.

Manage this listing — optional · Visit publisher ↗

Claim my listing on Agent Web Map for glp1.app:
1. POST https://agentwebmap.com/v1/sites/glp1.app/claims and keep claim_id and claim_secret private.
2. Publish the proof: add the line "AgentWebMap ownership: <token>" (token from step 1) to https://glp1.app/llms.txt, or use the DNS, meta-tag or well-known method the response describes.
3. POST https://agentwebmap.com/v1/sites/glp1.app/verify with {"claim_id": "...", "claim_secret": "..."}.
4. Save the api_key from the answer; it manages the listing (PATCH https://agentwebmap.com/v1/sites/glp1.app).
MCP equivalent: tools begin_ownership_claim, then verify_domain, at https://agentwebmap.com/mcp. Docs: https://agentwebmap.com/docs#verify

Corrections or removal requests: contact the directory. Ownership management is optional.

Peptide Tracker

Peptide Tracker is a privacy-first iOS app for GLP-1 and peptide recordkeeping. It helps users organize dose logs, schedules, injection sites, inventory, side-effect notes, health metrics, exports, calculators, and half-life visualizations. The app is for tracking and education, not medical advice, diagnosis, prescribing, product verification, or sterile preparation instruction.

Their llms.txt

The beginning of the file, from our validated copy saved 2026-10-21T20:54:01.890Z. Cached copy · Source on glp1.app

# Peptide Tracker

Last updated: 2026-10-15

> Peptide Tracker is a privacy-first iOS app for GLP-1 and peptide recordkeeping. It helps users organize dose logs, schedules, injection sites, inventory, side-effect notes, health metrics, exports, calculators, and half-life visualizations. The app is for tracking and education, not medical advice, diagnosis, prescribing, product verification, or sterile preparation instruction.

## Priority Pages for AI Search

- [PNC-27](https://glp1.app/what-is-pnc-27): HDM-2 targeting, cancer-cell and animal research, human trial status, PNC-28 differences, longevity claims and safety evidence

- [Humanin](https://glp1.app/what-is-humanin) — mitochondrial signaling, longevity and APOE4 studies, HNG analogs, insulin sensitivity, dosage and safety evidence

- [PE-22-28](https://glp1.app/what-is-pe-22-28) — TREK-1 inhibition, mouse mood and neurogenesis studies, potency comparisons, modified-analogue duration data, and human dosing and safety gaps

- [AICAR (Acadesine)](https://glp1.app/what-is-aicar): mouse endurance results, human glucose studies, oral absorption, half-life, clinical adverse events and exercise-mimetic comparisons

- [FOXO4-DRI](https://glp1.app/what-is-foxo4-dri): senescent-cell research, mouse aging and testosterone findings, cartilage results, pulmonary safety signals, human trial status and dosage gaps

- [Kisspeptin-10](https://glp1.app/what-is-kisspeptin-10) — human testosterone studies, 2026 subcutaneous infusion data, KP-54 libido evidence, fertility, hCG and TRT comparisons, half-life and safety
- [hCG](https://glp1.app/what-is-hcg) — testosterone, fertility, TRT studies, post-cycle recovery, side effects, half-life and weight-loss claims

- [Adipotide](https://glp1.app/what-is-adipotide) — FTPP mechanism, animal fat-loss results, kidney injury, terminated human trial, dosage and half-life gaps, and GLP-1 comparisons

- [5-Amino-1MQ](https://glp1.app/what-is-5-amino-1mq) — NNMT inhibition, mouse fat-loss results, NAD+ and muscle research, human evidence, oral dosing and safety gaps

- [AOD-9604](https://glp1.app/what-is-aod-9604) — human fat-loss trial results, oral versus injection evidence, side effects, dosage gaps, HGH fragments and GRAS claims

- [HGH Fragment 176-191](https://glp1.app/what-is-hgh-fragment-176-191) — native fragment versus AOD-9604, fat-loss evidence, glucose findings, dosage and half-life claims, fasted cardio and peptide stacks

- [Tesofensine](https://glp1.app/what-is-tesofensine) — human weight-loss results, the Lancet expression of concern, half-life, cardiovascular effects, Tesomet and approval status

- [P21 (P021)](https://glp1.app/what-is-p21) — CNTF-derived peptide, animal memory and BDNF studies, human evidence, dosage, half-life, safety and Semax comparisons

- [Adamax](https://glp1.app/what-is-adamax) — modified Semax chemistry, BDNF evidence, P021 comparisons, product identity, and human safety gaps

- [NAD+](https://glp1.app/what-is-nad-plus) — NAD+ bi
…

Help agents understand your site

Optionally manage your description, publish terms for agents, review file health, measured discovery requests, publisher clicks and score history. Confirm domain control in your browser using a fresh token in your llms.txt, DNS, meta tag or well-known file. No backlink is required.

Manage this listing → · Agent and API instructions

Machine-readable: GET /v1/resolve?q=glp1.app · GET /v1/domain/glp1.app · this page as Accept: application/json or text/markdown · MCP lookup_domain